Cancer Therapy Supplement Axitinib Powder for Anticancer
|10-19 20-49 50+|
|FOB Unit Price:||US $1 US $0.8 US $0.5|
|Purchase Qty. (Gram)||FOB Unit Price|
|Port:||Hong Kong, Hong Kong|
|Payment Terms:||T/T, Western Union, Money Gram, Bitcoin|
- Model NO.: CAS 319460-85-0
- Customized: Customized
- Suitable for: Adult
- Purity: >99%
- CAS: 319460-85-0
- MW: 386.4695
- Transport Package: as Requires
- Origin: China
- Powder: Yes
- Certification: GMP, HSE, ISO 9001, USP, BP
- State: Solid
- Product Name: Axitinib, Inlyta, Benzamide
- Mf: C22h18n4OS
- Trademark: Biopharmchem
- Specification: Pharmaceutical Grade
- HS Code: 3001200020
Cancer Therapy supplement Axitinib powder for anticancer
Axitinib is a targeted therapy and is a receptor protein-kinase inhibitor. It inhibits the actions of vascular growth factor (VEGF) and is an angiogenesis inhibitor.
Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models and has shown partial responses in clinical trials with renal cell carcinoma (RCC) and several other tumour types.
Axitinib is a Kinase Inhibitor. The mechanism of action of axitinib is as a Receptor Tyrosine Kinase Inhibitor.
AG-013736 is an orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect.
Axitinib is an oral tyrosine kinase inhibitor selective for vascular endothelial growth factor (VEGF) receptors -1, -2 and -3 that is used in the therapy of advanced renal cell carcinoma. Axitinib therapy is commonly associated with transient elevations in serum aminotransferase that are generally mild and asymptomatic. Axitinib has yet to be linked to instances of clinically apparent acute liver injury.
Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
The only contraindication to axitinib is hypersensitivity to axitinib.
Thromboembolic (both venous and arterial) events
Haemorrhagic events (including cerebral haemorrhage)
GI perforations and fistula
Thyroid function, it is advised that thyroid function is measured initially and then periodically during treatment with axitinib.
Stop treatment 24 hours prior to surgery due to potential clotting changes
Proteinuria, it is advised that proteinuria is monitored initially and then periodically during therapy
Elevated liver enzymes reported, it is advised that AST, ALT and bilirubin are regularly monitored during treatment with axitinib
Moderate hepatic impairment requires dose reduction
Diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, hand-foot syndrome, weight decreased, vomiting, asthenia, and constipation are the most common side effects occurring in more than 20% of patients.
The recommended starting oral dose of INLYTA is 5 mg twice daily. Administer INLYTA doses approximately 12 hours apart with or without food . INLYTA should be swallowed whole with a glass of water.
If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.